Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aurinia Pharm Ord
(NQ:
AUPH
)
6.260
+0.670 (+11.99%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aurinia Pharm Ord
< Previous
1
2
3
4
5
6
Next >
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results
August 01, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024
July 19, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia to Participate in Upcoming Investor Healthcare Conferences
July 02, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces 2024 Annual General Meeting Results
June 14, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
June 05, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
June 04, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Provides Update on Proxy Statement
June 03, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
May 30, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
May 14, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
May 09, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
May 07, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
May 02, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
May 01, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
April 30, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
April 16, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
April 15, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
April 09, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
February 29, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia to Participate in Upcoming Investor Healthcare Conferences
February 27, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
February 15, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024
February 05, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results
January 05, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Submits IND Application to US Food & Drug Administration for AUR 200
December 20, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan
November 13, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023
November 07, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis
November 02, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
November 02, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis
October 26, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023
October 19, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)
October 13, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.